Coverage
-
February 12, 2026
Regeneron Pharmaceuticals Inc. and Samsung Bioepis Co. Ltd. have told a West Virginia federal court they reached an agreement to end patent infringement claims brought by Regeneron over a biosimilar of its eye medication Eylea.
2 other articles on this case.
View all »